SecBot SecBot
SC 13G/A ·Filed Nov 4, 2026

EQ

Equillium, Inc.
NEUTRAL
Impact 2/10
Horizonimmediate Processed17d 22h ago SEC0001716774-26-000029
Passive stake amendment
Actionable Insight • Neutral

No change in investment intent or material stake movement. Monitor for any future conversion to Schedule 13D or significant position changes.

DirectionNeutral
Confidencehigh
Horizonimmediate

How the stock moved after the report

NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+5
Entry
$1.40
T+0 close · Nov 4, 2026 · via day close
Latest settled
+1.43%
T+5 · $1.42 · next T+20 in 11d
Vs SPY
+2.34%
α at T+5
Latest observation
−24.05%
T+12 · FF3 residual α
  1. T+0 · Nov 4 $1.40entry
  2. T+1 · 17d ago −5.00%α −0.59% · $1.33
  3. T+5 · 11d ago +1.43%α +2.34% · $1.42
  4. T+12 · todayOpen
  5. T+20 · in 11d Pending
  6. T+60 · in 2mo Pending

Price Chart

Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Aberdeen Group plc filed an amended Schedule 13G disclosing a 7.03% passive stake in Equillium, Inc., representing 4,458,351 shares as of September 30, 2026. This is a routine passive update with no change in investment intent.

Key Financial Metrics

Stake
7.03%
Investor
Aberdeen Group plc
Investor Type
mutual fund

Key Facts

  • Aberdeen Group plc reported beneficial ownership of 4,458,351 shares of Equillium common stock
  • Stake represents 7.03% of shares outstanding as of September 30, 2026
  • Filing is an amendment to Schedule 13G, indicating passive investment intent
  • Shares are held through subsidiary abrdn Inc. on behalf of underlying clients

Financial Impact

Stake valued at approximately $7.5M based on $107M market cap and 7.03% ownership

ownership_percentage

Risk Factors

  • Passive filing; no indication of activist intent or strategic change
  • No prior stake size disclosed for comparison in this filing

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
94% bullish (18 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
SC 13G/A Filing (Primary)0001716774-26-000029
Document: 0001716774-26-000029-index.html0001716774-26-000029
Document: 0001716774-26-000029.txt0001716774-26-000029

Track record

20 reports on EQ

Performance horizon

2 of 3 bullish or bearish reports moved the stock their way by T+1. Best: +20.40% at T+60 after the Jun 5, 2026 report. 2 of 3 went positive at some point.

Filters
  1. Nov 20, 20262d ago EFFECT Neutral 4/10 Entry $1.12 Now $1.06 −5.36% settles Nov 23
  2. Nov 16, 20265d ago SC 13G/A Neutral 3/10 Entry $1.21 to $1.10 Now $1.06 −12.40% ▼ −9.09% −8.79% vs SPY
  3. Nov 13, 20268d ago SC 13G/A Neutral 2/10 Entry $1.15 to $1.21 Now $1.06 −7.83% ▲ +5.22% +6.23% vs SPY
  4. Nov 12, 20269d ago S-3 Neutral 4/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
  5. Nov 12, 20269d ago 8-K Neutral 5/10 Entry $1.29 to $1.15 Now $1.06 −17.83% ▼ −10.85% −8.94% vs SPY
  6. Nov 12, 20269d ago SC 13G/A Neutral 2/10 Entry $1.32 to $1.29 Now $1.06 −19.70% ▼ −2.27% −1.91% vs SPY
  7. Nov 4, 202617d ago SC 13G/A Neutral 2/10 Viewing Entry $1.40 to $1.33 Now $1.06 −24.29% ▼ −5.00% −0.59% vs SPY
  8. Oct 26, 202626d ago 8-K Bearish 6/10 Entry $1.36 to $1.42 Now $1.06 +22.06% ▼ −4.41% −4.07% vs SPY
  9. Oct 26, 202626d ago Press Release Neutral 4/10 Entry $1.25 to $1.36 Now $1.06 −15.20% ▲ +8.80% +8.24% vs SPY
  10. Oct 5, 20266w ago 8-K Neutral 3/10 Entry $1.42 to $1.39 Now $1.06 −25.35% ▼ −2.11% −1.87% vs SPY
Showing 10 of 20

US Market Status

Market Closed · Opens Mon (26h 20m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Nov 4, 2026